Samuel Berngard, MD
Pulmonary Disease · Boulder, CONPI 1265708622
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $61,461 of the $73,002 with a category attached, or 84.2%. Actelion Pharmaceuticals US, Inc. accounts for 98.9% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $18,128, more than ten times the $162 reported in 2019. Among pulmonary disease clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 209 payments — averaging $349.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$72K
- Inspire Medical Systems, Inc.$207
- GSK$124
- Aerin Medical Inc.$84
- Insmed, Inc.$70
- Intuitive Surgical$62
- plus $254 from 10 others
What the payments were for
- Consulting fees$4,0406%
- Speaking & faculty fees$61,46184%
- Travel & lodging$3,5325%
- Food & beverage$3,8035%
- Education$1660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 177 | $72,201 |
| Inspire Medical Systems, Inc. | 6 | $207 |
| GSK | 4 | $124 |
| Aerin Medical Inc. | 3 | $84 |
| Insmed, Inc. | 3 | $70 |
| Intuitive Surgical | 1 | $62 |
| Genentech USA, Inc. | 1 | $38 |
| United Therapeutics Corporation | 6 | $35 |
| Lilly USA, LLC | 1 | $31 |
| AstraZeneca | 1 | $29 |
| Boston Scientific | 1 | $28 |
| Bayer | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Pulmonx Corporation | 1 | $17 |
| Resmed Corp | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$73,002 in reported general payments places this provider in the 90th percentile of 248 pulmonary disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 43 | $550,509 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 285 | $326,938 |
| OfevNintedanib Esylate | 17 | $250,961 |
| AdempasRiociguat | 13 | $183,140 |
| EliquisApixaban | 58 | $83,594 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 121 | $82,684 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 67 | $73,944 |
| Dupixent PenDupilumab | 16 | $61,362 |
| Breo ElliptaFluticasone/Vilanterol | 76 | $56,470 |
| JardianceEmpagliflozin | 44 | $49,491 |
| MounjaroTirzepatide | 26 | $28,307 |
| Advair HfaFluticasone Propion/Salmeterol | 37 | $19,136 |
| DuleraMometasone/Formoterol | 39 | $18,303 |
| XareltoRivaroxaban | 11 | $18,216 |
| Tadalafil | 23 | $14,993 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $72,201 | $550,50943 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $124 | $473,952496 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Jardiance | $19 | $374,396128 claims |
| BayerAdempas | $21 | $183,14013 claims |
| Lilly USA, LLCMounjaro | $31 | $28,30726 claims |
| AstraZenecaSymbicort | $29 | $11,96725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 248 pulmonary disease providers in Colorado.
Other pulmonary disease in Boulder
- Michael WechslerDenver$2.7M
- Ronald BalkissoonDenver$1.2M
- David SchwartzAurora$471K
- Vamsi GunturDenver$310K
- Kevin BrownDenver$299K
- Rebecca KeithDenver$248K
- Joshiah GordonPueblo$208K
- Marjorie GeorgeDenver$192K
- Everett SutherlandDenver$174K
- Charles DaleyDenver$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.